NuGene International, Inc. Adds Dr. Dendy Engelman to Board of Advisors

IRVINE, Calif., March 3, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the maker of age-defying aesthetic products for skin and hair rejuvenation, has augmented its distinguished board of advisors with the inclusion of Dr. Dendy Engelman, Director of Dermatological Surgery at New York Medical College.

"Dr. Engelman exemplifies the quality of character, experience and leadership that we seek in our advisory board," stated Ali Kharazmi CEO of NuGene. "Her humanitarian efforts, awards and history reflect her desire to help people while providing the best patient experience possible. As a dermatological surgeon, she experiences on a daily basis many of the challenges that we seek to address through our NuGene technology."

Dr. Engelman is a board certified dermatologic surgeon and an associate at Manhattan Dermatology & Cosmetic Surgery. She attended Wofford College and was inducted into Phi Beta Kappa, graduating summa cum laude with honors. Dr. Engelman has earned the Presidential Scholar award and was also awarded the Humanism in Medicine Scholarship. Dr. Engelman has extensive training and experience in cosmetic dermatology –including neurotoxins, injectable fillers, and chemical peels.

She is a fellow of the American Academy of Dermatology, American Society of Dermatologic Surgery and American College of Mohs Surgery (a procedure that removes skin cancer under local anesthetic). Most recently, Dr. Engelman was appointed Director of Dermatologic Surgery at New York Medical College where she oversees the training of future Mohs surgeons and dermatologists.

"The possibilities for NuGene are very exciting," said Dr. Engelman. "Their current product lines for skin and hair care are exemplary, and I am even more excited about the opportunities with their new BioPharma subsidiary. Combining the NuGene technology with complementary products should be extremely interesting, and I have the opportunity to see the developments first hand."

NuGene has recently announced the formation of a new subsidiary, NuGene BioPharma, Inc. to focus on stem cell derived treatments that may require FDA approval. The company intends to acquire and develop pharmacological treatments that can relieve skin conditions such as acne, eczema, burns and other dermatological conditions.

About NuGene International, Inc.

Nugene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.   The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments".  The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.  NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue.  NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations.  The company has two patents pending covering 15 unique applications and inventions.  NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.These forward-looking statements generally can be identified by use of phrases or terminology such as "anticipate," "believe," "continue," "could," "hope," "target," "project," "goal," "objective," "guidance," "plan," "potential," "predict," "might," "estimate," "expect," "intend," "may," "seek", "should," "target," "will," "would," "look forward" and other similar words or expressions, or expressions, or the negative of these words or similar words or expressions. Similarly, descriptions of NuGene's objectives, strategies, plans or goals or targets contained herein are also considered forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission from time to time, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information whether as a result of new information, future events or otherwise. All of the forward-looking statements contained herein speak only as of the date of this release.

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949)481-9739

Logo - http://photos.prnewswire.com/prnh/20150303/179172LOGO

SOURCE NuGene International, Inc.